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Abstract
Objective—To address the need for standardization of osteoarthritis (OA) phenotypes by
examining the effect of heterogeneity among symptomatic (SOA) and radiographic osteoarthritis
(ROA) phenotypes.
Methods—Descriptions of OA phenotypes of the 28 studies involved in the TREAT-OA
consortium were collected. To investigate whether different OA definitions result in different
association results, we created hip OA definitions used within the consortium in the Rotterdam
Study-I and tested the association of hip OA with gender, age and BMI using one-way ANOVA.
For radiographic OA, we standardized the hip, knee and hand ROA definitions and calculated
prevalence's of ROA before and after standardization in 9 cohort studies. This procedure could
only be performed in cohort studies and standardization of SOA definitions was not feasible at this
moment.
Results—In this consortium, all studies with symptomatic OA phenotypes (knee, hip and hand)
used a different definition and/or assessment of OA status. For knee, hip and hand radiographic
OA 5, 4 and 7 different definitions were used, respectively. Different hip OA definitions do lead to
different association results. For example, we showed in the Rotterdam Study-I that hip OA
defined as “at least definite JSN and one definite osteophyte” was not associated with gender
(p=0.22), but defined as “at least one definite osteophyte” was significantly associated with gender
(p=3×10−9). Therefore, a standardization process was undertaken for radiographic OA definitions.
Before standardization a wide range of ROA prevalence's was observed in the 9 cohorts studied.
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After standardization the range in prevalence of knee and hip ROA was small. Standardization of
SOA phenotypes was not possible due to the case-control design of the studies.
Conclusion—Phenotype definitions influence the prevalence of OA and association with
clinical variables. ROA phenotypes within the TREAT-OA consortium were standardized to
reduce heterogeneity and improve power in future genetics studies.
Introduction
The Translational Research in Europe Applied Technologies for OsteoArthritis (TREAT-
OA) consortium was established in January 2008 to address the generalisability and utility
of genetic and biochemical risk factors (www.treatoa.eu). The two main goals of TREAT-
OA are 1) to develop efficient diagnostics for risk and progression of osteoarthritis (OA) and
2) to identify new targets for therapeutic interventions. This will be done by identification of
genes and biochemical markers consistently associated with risk and progression of OA, but
also by defining the roles of these genes in molecular pathways involved in disease
aetiology, for example by the development of in vivo transgenic animal OA model systems.
A major goal of the consortium is to identify new genes consistently associated with risk and
progression of OA. To reach this goal, large-scale genome-wide association studies
(GWASs) and meta-analyses are being performed. To date, research within the TREAT-OA
consortium has resulted in the identification of a novel genetic locus on chromosome 7q22
that is associated with knee- and hand OA1, which was confirmed by a yet unpublished
GWAS meta-analysis on knee OA. In addition, the ataxin 2 binding protein 1 gene2 and the
prostaglandin-endoperoxide synthase 2 gene3 have been found associated with respectively
hand and knee OA. One of the difficulties in these genetic analyses, and also in general in
epidemiological research of OA is heterogeneity of the definition of the phenotype under
study. Heterogeneity of the definition of the phenotype among different studies reduces
power to find consistent associations in any disease4. Two working groups of HuGEnet and
NCI-NHGRI have published recommendations for replication studies in genetic
epidemiology studies5–7. One of their recommendations was to try to investigate the same or
a very similar phenotype in replication studies. Specifically for OA, the American College
of Rheumatology (ACR) criteria were developed to define clinical OA within a secondary
care setting8 and the OARSI-OMERACT initiative proposed definitions for radiological
progression of hip and knee OA9. The problem of heterogeneity in genetic association
studies of OA has been highlighted10 and therefore standardized radiographic OA (ROA)
phenotypes were used in our recent GWAS and subsequent meta-analysis1. However,
symptomatic (SOA) and ROA phenotypes were both used within the same meta-analysis.
For ROA, several grading systems exists, but the most widely and consistently used system
is the Kellgren and Lawrence (K/L) grading system11. Among major cohort studies, K/L
scores are interpreted differently, especially for the knee and hip, despite the fact that they
all refer to the original description12–14.
In the current study, we will examine the effect of heterogeneity among symptomatic (SOA)
and radiographic osteoarthritis (ROA) phenotypes and address the need for standardization




We collected data for 28 studies currently involved in the TREAT-OA consortium on the
following 9 items: 1) reference article, 2) study design, 3) ethnic origin, 4) country of origin,
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5) joint site(s) studied 6) radiographic or symptomatic OA definition, 7) availability of age
and/or BMI data, 8) percentage of women in the study and 9) availability of follow-up data.
Table 1 describes the characteristics of all studies evaluated. A short description of each
study is given in the supplementary data.
OA definitions
OA phenotypes can be categorized into symptomatic OA and radiographic OA, and this
information was collected from all studies. Subsequently, we asked for the exact OA
definition used in that particular study. For example, if a study used a K/L score and used
the cut-off value defined by a summary grade of 2 or more to define OA cases, the exact
description of a K/L of 2 was requested (e.g. definite osteophytes with possible JSN versus
definite osteophyte(s) only) or a reference article was asked were the exact interpretation of
the K/L score was given.
Data analysis of OA phenotypes within the Rotterdam Study I (RSI)
Within RSI radiographic features are scored separately for hip OA (such as osteophytes,
sclerosis and joint space narrowing at the lateral, superior and axial site of the hip joint)15. In
addition, total hip replacement and the presence of pain during the last month are recorded.
To discover if differences in case definitions result in different association results, we
created all hip OA case definitions used by studies of the consortium within RSI.
Association analyses were performed to study the relationship between different OA
definitions of the hip and age, gender and body mass index (BMI). One-way ANOVA was
used to assess the relationship between hip OA and the clinical variables. The analyses were
carried out using SPSS version 15.0.
Standardization of phenotypes
Consensus on which ROA phenotype to use within the TREAT-OA consortium was based
on the ROA definition as originally described by Kellgren and Lawrence and the feasibility
of its use within each of the studies11. Total joint replacements (TJR) due to primary OA
visible on radiographs are considered as OA. TJR due to fractures and other diseases were
excluded as much as possible. After a consensus was reached between consortium members,
the cohort studies either shared their data with our research group (Rotterdam Study) who
standardized the definitions (data of TwinsUK, Chingford Study) or performed the
standardization process themselves (other replication studies) if they were able and willing
to standardize their ROA definition. The prevalence of OA was calculated by dividing the
number of prevalent ROA cases over controls. Before standardization, controls were defined
as the absence of OA, according to the definition used by each study, at the joint site
studied. After standardization, controls were defined as the absence of OA, according to the
standardized definition as described in the results section, at the joint site studied.
Results
Study Populations
Since the start of the TREAT-OA consortium in 2008, the number of teams collaborating
with the consortium has grown to include 28 teams participating as of April 2010. The
studies originate from Europe, the United States of America and Asia. In 24 of the 28
studies (86%), the majority of subjects included are women (63% on average). With respect
to genetic data, there are in total 11 studies with GWAS data, 2 studies in which part of the
subjects have GWAS data and 15 studies without GWAS data. A short description of all
studies involved in the consortium is given in the supplementary data.
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In total, there were 11 studies using a symptomatic definition of OA and 15 studies with a
radiographic definition. Two studies could not be classified as completely symptomatic or
radiographic (SOA/ROA). For the GARP Study, subjects were recruited with clinical and
radiographic confirmed OA at two or more joint sites among hand, spine, knee or hip16. If a
subject was selected on the basis of hip and hand SOA for example, but the objective of a
future study is knee OA, this subject might have ROA of the knee. We can neither call this
pure knee ROA nor SOA since the subject was selected on the basis of having symptoms of
generalized OA, but the assessment of knee OA is radiographic. In addition, the Finnish
cases consist of 2 subsets with subjects affected with SOA and ROA of the hand and
affected siblings with ROA of the hand17. In this study, we have chosen to classify the
GARP Study and the Finnish cases as studies with SOA/ROA.
Radiographic OA (ROA)—For knee OA, there are 14 studies using radiographic
definitions of knee OA shown in Table 2a with a detailed description of the knee ROA
definition. A total of 12 studies used the K/L score, of which 11 studies used a cut-off value
of 2 to define knee ROA and 1 study used a more stringent cut-off of 3. Two studies, which
are both high risk cohorts, used a definition of OA not according to a standard classification
system. As is shown in Table 2a, four different interpretations are given for the K/L score of
the knee considering a cut-off value of 2 although all studies used the original K/L atlas. In
Table 2b–c, results are given for hand- and hip ROA respectively in a similar way as for
knee ROA.
For hand ROA, most studies (7 out of 9) used the K/L score to define hand OA, with the
exception of two studies16,17. The interpretation of this K/L score is the same for all these
studies, but there are 4 different hand ROA definitions based on the number of joints
included.
Hip ROA was defined by the (modified) Croft grade in 3 studies and by the K/L score in 4
studies. Also for hip ROA there is no consensus on the interpretation of the K/L score as 2
different interpretations are present among the studies. This includes both “definite JSN and
a definite osteophyte” OR “one definite osteophyte”. The Croft grade cut off of 1 as a
criterion for hip ROA, is defined as definite osteophytes and does not include JSN.
Symptomatic OA (SOA)—For knee OA, there are 10 studies using clinical definitions of
knee OA, which are shown in Table 3a. In total, 4 of these 10 studies defined knee OA as
ROA + symptoms, but the inclusion of patients was done in 4 different ways. For example,
one study used a K/L score ≥ 2 (defined as one definite osteophyte) + medial joint space > 1
mm + pain to include patients, whilst another study used a K/L score ≥ 3 + symptomatic OA
and treated on a regular basis. The other 6 studies included patients on the basis of total joint
replacements due to primary OA or a combination of a TJR or ROA and clinical symptoms
of OA.
In Table 3b–c, results are given for hand (n=2) and hip (n=8) SOA respectively in a similar
way as for SOA of the knee. Also, these definitions differed for each study. In summary,
hand SOA was defined by either ACR criteria or by patient records. Hip SOA was defined
as a THR by 3 studies although the assessment was different for all 3 studies (i.e., based on
hospital records versus based on the description of a rheumatologist). In addition, 2 studies
defined SOA of the hip as symptoms of OA + ROA, but the definition of ROA is unclear
and inclusion based on symptoms differs. Furthermore, there were 3 additional studies
defining hip SOA again in another way (i.e., incident THR or either clinical records of SOA
or a THR).
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Data analysis of OA phenotypes within the Rotterdam Study I (RSI)
In Table 4, association results are given for the relationship between age, gender and BMI
and different hip OA definitions. When hip OA was defined radiographically as “one
definite osteophyte” subjects with hip OA were more frequently men compared to controls
(mean difference of 10%, p=3×10−9), whilst subjects with a THR were more frequently
women compared to controls (mean difference of 21%, p=0.001). When radiographic OA
definitions were compared, we observed that hip ROA defined as “one definite osteophyte”
were more frequently men compared to controls (p=3×10−9), whilst hip OA defined as
“definite JSN and one definite osteophyte” was not associated with gender (p=0.22). When
analyzing SOA, we did not observe clear differences in association results for the different
definitions of SOA, but the number of cases for SOA is much lower than for ROA, therefore
results should be taken with caution.
Standardization of phenotypes
Consensus was reached for the knee and hip OA definition based on the ROA definition as
originally described by Kellgren and Lawrence11 and at the feasibility within each of the
studies. It was agreed that the knee ROA definition used within the TREAT-OA consortium
is the original K/L score11 defined as “definite osteophytes and possible joint space
narrowing” at the tibio-femoral (TF) joint. If studies did not score possible JSN as a separate
feature, the definition used was: “at least 2 definite osteophytes OR one definite osteophyte
plus definite JSN”. Hip ROA, which was the most poorly specified in the original scores,
was defined as “at least definite joint space narrowing”. For hand ROA, consensus was not
reached within the consortium, due to the fact that different studies graded different joints
for hand OA, thus limiting the possibility to generate a single definition. As an alternative,
thumb OA was put forward as an interesting phenotype to study, because of the high
correlation with pain and disability18. Consensus was reached on a definition for thumb OA
which is “at least one definite osteophyte (= original K/L grade ≥ 2) in either the left or right
first carpometacarpal (CMC1) joint”.
In Table 5, the number of cases and controls for each study are given after standardization of
phenotypes (both SOA and ROA). In total, there are 13,119 knee OA cases and 61,538
controls, 9,521 hip OA cases and 59,345 controls and 4,913 hand OA cases and 41,863
controls with DNA and phenotype data within the TREAT-OA consortium.
To evaluate the effect of standardization of the ROA phenotypes, we calculated the
prevalence of knee and hip ROA in 8 Caucasian and 1 Japanese cohort study before and
after standardization of the ROA definition. In Table 6, the mean age and BMI are shown
for the 9 cohorts. The Framingham Osteoarthritis Study, The Hertfordshire Cohort Study,
The Osteoporotic Fractures in Men Study, The Rotterdam study I, the ROAD Study and the
Study of Osteoporotic Fractures are on average 14 years older than The Chingford Study,
the Rotterdam Study III and TwinsUK. The result of the standardization of knee and hip OA
phenotypes is shown in Figure 1. Results for the thumb OA phenotype are not shown since
all studies use the same definition. The standardized hip OA definition is “at least definite
JSN or a THR visible on the radiograph due to primary OA”. In the SOF and MrOS Study a
minor adjustment was made and hip ROA was defined as: “at least medial JSN (grade≥3) or
lateral JSN (grade≥2) or a THR visible on the radiograph due to primary OA”. The
standardized knee ROA definition is “at least definite osteophytes and possible JSN or a
TKR visible on the radiograph due to primary OA”.
Before standardization the prevalence of knee OA ranged between 10–55%, of hip OA
between 2–33%. After standardization the prevalence of knee OA ranged from 8–25% and
hip OA between 4–10%. When comparing cohorts with the same age range, the prevalence
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of knee ROA was 8–12% in the younger cohorts and 16–25% in the cohorts with subjects of
an older age. To show that the differences in age are indeed the cause of the lower
prevalence of knee OA in 3 cohort studies, we studied the prevalence of knee ROA in one
relatively young and one old cohort with a wide age range, respectively TwinsUK and RS-I.
The prevalence of knee ROA ranged from 10–15% in subjects aged 65 years and younger.
In subjects aged 65 years and older, the prevalence ranged from 29–34% for the 2 studies.
Discussion
A wide range of OA definitions were used in the 28 studies participating in the TREAT-OA
consortium. Since heterogeneity in phenotype definitions will reduce power to find
consistent associations, radiographic OA phenotypes were standardized within the
consortium.
There are some research fields in which specific attention is given to phenotype definitions.
This mainly concerns studies in the field of neuroscience (i.e., bipolar disorder or
schizophrenia)19 and obesity20. In contrast, published research involving osteoarthritis,
osteoporosis and heart disease does not usually discuss phenotype definitions. Our results
showed that OA definitions should be standardized since association results differ when
varying ROA and SOA definitions are used within the same study. In addition, it was
recently shown that the ability to detect hip OA genetic associations is influenced by proper
phenotyping21. We showed by standardizing of ROA phenotypes, that similar ROA
prevalence's could be obtained.
For hip ROA, a distinction can be made between atrophic OA (presence of JSN without
osteophytes), hypertrophic OA (presence of osteophytes without JSN) or a composite score
(both JSN and osteophytes)22. It is known that these different forms of hip ROA have
different risk factors23,24. In addition, atrophic OA shows to be a more progressive form of
OA than hypertrofic OA25. Since some studies interpret a K/L score ≥ 2 as one definite
osteophyte, whereas other studies interpret this as definite JSN and one definite osteophyte,
a difference in association results would be expected. Although the standardized definition
agreed upon by the consortium is based on JSN (hip ROA = at least definite JSN, with or
without osteophytes), a majority of the subjects (78 and 80% in the Rotterdam Study-I and
III, respectively) have both JSN and osteophytes. This definition can therefore also be seen
as a composite score. Although less often used than the composite score of hip ROA,
hypertrophic hip and atrophic hip ROA definitions should also be standardized. We suggest
using “presence of at least one definite osteophyte at the femoral head without definite JSN”
as preferred definition for hypertrofic OA and “definite JSN without the presence of any
osteophytes at all locations” as atrophic OA which was also used in a previous study by
Javaid et al.22.
It was difficult to reach consensus on the hand ROA definition, since different studies scored
different joints. To overcome this problem, a subtype for clinically relevant OA was
suggested within the consortium: thumb OA, associated with pain and disability18,26, will be
used within the consortium. The definition of ROA of the thumb is “at least one definite
osteophyte in either right or left CMC1 joint”.
We recommend for future studies on ROA to always specify the exact OA definition. A
statement such as “we defined OA as a K/L ≥ 2” should be avoided or the interpretation of
this K/L score should be given.
Since all studies involved in the consortium defined SOA differently, or at least assessed the
OA status differently, it is likely that heterogeneity is a problem in studies on SOA.
Standardization of SOA would in principle be possible if studies had pain, clinical
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assessment data for study subjects, as well as radiographic grade for the index joints, age,
BMI, for both cases and controls. The design of some studies is such however that there is
no radiographic characterization for cases and controls, which is necessary if SOA would be
defined based on both symptoms and radiographs, and only a diagnosis of TJR for an
indication of OA is present. These are extant studies and to collect homogenous SOA studies
would require a huge investment of resources as well as time. However, there remains a lack
of consensus and guidelines about how SOA should be assessed. For example, the American
College of Rheumatology (ACR) defines signs of OA as stiffness <30 minutes, crepitus,
bony tenderness, bony enlargement, no palpable warmth and pain in or around the joint. The
presence of these traits in subjects over the age of 50 (preferably accompanied by
radiographic evidence of OA) is commonly used in the design of randomized clinical trials
(RCTs)27. But these criteria were developed in a clinic setting so the sensitivity and
specificity of a diagnosis based on these criteria in a community or primary care settings, are
as yet unknown.
Most of the SOA cases included in the TREAT-OA consortium are total joint replacement
cases with a primary indication of OA. Although it is possible to define TJR as the main
clinical outcome representative of severe symptomatic large joint OA in itself, as has been
proposed for RCTs28, this might not be the best option. Recent studies on this topic have
revealed considerable heterogeneity in the radiographic severity, functional disability and
pain suffered by TJR candidates29. In addition, the pain and disability components among
subjects undergoing TJR are significantly correlated with risk factors that also impact on
ROA such as BMI, age, sex, whilst being poorly correlated with radiographic severity29,30.
Further, not all patients with severe symptomatic OA can or are willing to get a TJR either
because of lack of access to healthcare, or they may be afraid of surgery, or have co-
morbidities that make them ineligible etcetera31. TJR patients are usually recruited in
secondary care settings and might in some instances represent a non-random subset of
severe symptomatic OA.
In summary, additional research is needed to reach consensus for in- and exclusion criteria
and definitions of clinical/symptomatic OA studies. We suggest that more thought should be
given to the establishment of clear guidelines for future research using symptomatic OA
cohorts, as this would have implications not just for genetic studies, but also for the
assessment of biomarkers, imaging and interventional studies.
Genome-wide association studies (GWAS) and meta-analyses have been1,32 and will
continue to be performed within the TREAT-OA consortium in order to identify genes
consistently associated with risk and progression of OA. Presently, there are few genes
discovered for OA by means of GWAS, and this may be explained by heterogeneity of
phenotypes and the limited sample size used in the discovery GWAS samples up to now.
For example, in a previous GWAS, ROA and SOA definitions were used within one meta-
analysis1. It has been shown before that ROA shows only modest correlation with clinical
features of OA33,34. In addition, we showed in this study that the association between SOA
and age, gender and BMI is different compared to ROA. Although the sample size would
decrease using stratification methods, the statistical power might increase if there is a
reduction in the heterogeneity in the phenotype definition. Therefore, we recommend that
for future GWASs additional work is needed to standardize or stratify on ROA and SOA.
Fortunately, in the TREAT-OA consortium studies on ROA have access to the source
material and individual features of ROA are scored separately. This enables us to easily
establish standardized phenotypes across cohorts.
Additionally, other phenotypes or possible predictors such as hypertrophic vs. atrophic
forms of OA, joint shape, MRI based features, severe ROA (K/L≥3 versus K/L=0) or
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generalized OA may expand our definitions of the OA phenotypes and may increase the
number of consistent associations in genetic studies. However, consensus among OA
epidemiologist on OA phenotypes should be reached within the OA field, prior to the
performance of these association studies.
In conclusion, standardization of radiographic OA phenotypes was carried out in the
TREAT-OA consortium to reduce heterogeneity as much as possible. Standardization of
symptomatic OA phenotypes, although desirable, was not possible due to the case-control
study design of the studies. In the future, more precise OA phenotypes and stratification
according to symptomatic and radiographic OA phenotypes are highly recommended.
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1. Future studies on OA should always specify the exact OA definition. A
statement such as “we defined OA as a K/L ≥ 2” should be avoided or the
interpretation of this K/L score should be given.
2. The use of standardized ROA definitions is recommended in association studies
with knee ROA defined as “at least 2 moderate definite osteophytes and possible
JSN at the tibio-femoral joint”, hip ROA as “at least definite JSN” and thumb
ROA as “at least one moderate definite osteophyte at the CMC1 joint”.
3. Atrophic hip ROA is suggested to be defined as “definite JSN without the
presence of any osteophytes at all locations” and hypertrophic hip ROA as
“presence of at least one moderate definite osteophyte at the femoral head
without definite JSN”.
4. Consensus is needed on in- and exclusion criteria and phenotype definitions of
SOA studies. More thought should be given to the establishment of clear
guidelines for future research using clinical OA cohorts
5. For future GWASs additional work must be done to stratify on age/BMI and
especially ROA and SOA.
6. Expansion of OA phenotypes is not discouraged. Other phenotypes such as
joint shape, MRI based features, severe ROA (K/L ≥ 3 versus K/L = 0) or
generalized SOA/ROA may expand our definitions of the OA phenotypes, but
consensus among OA epidemiologist on these new OA phenotypes should be
reached, prior to the performance of these association studies.
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Prevalence of knee and hip OA before and after standardization of the ROA phenotypes.
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Table 2a






Chingford Study K/L score 2 One definite osteophyte
Estonian Studies K/L score 2 Definite osteophytes
Finnish cases K/L score 3 Definite osteophytes + definite JSN and/or joint deformation
Framingham Osteoarthritis Study K/L score 2 Definite osteophytes and possible JSN
GARP K/L score 2 Definite osteophytes and possible JSN
HCS K/L score 2 Definite osteophytes
Japanese Cohort Study K/L score 2 One definite osteophyte
KANON - -
JSN grade ≥ 2 or sum of 2 marginal osteophyte grades from
the same compartment ≥ 2 or grade 1 JSN + grade 1
osteophytes in the same compartment
LUMEN - -
JSN grade ≥ 2 or sum of 2 marginal osteophyte grades from
the same compartment ≥ 2 or grade 1 JSN + grade 1
osteophytes in the same compartment
RSI K/L score 2 Definite osteophytes and possible JSN
RSII K/L score 2 Definite osteophytes and possible JSN
RSIII K/L score 2 Definite osteophytes and possible JSN
The ROAD Study K/L score 2 One definite osteophyte
TwinsUK K/L score 2 One definite osteophyte
K/L = kellgren and Lawrence; JSN = joint space narrowing; - no standard classification system is used to define OA; GARP = Genetics
osteoARthritis and Progression; HCS = Hertfordshire Cohort Study; RS = Rotterdam Study
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Table 2b
Description of the radiographic hand OA definition according to 9 studies of the TREAT-OA consortium




Chingford Study K/L score 2 ≥3 joints (DIP/PIP/CMC1) affecteda
D&TStudy Modified K/L score 2 ≥2 joints (DIP/PIP/MCP) affectedb
Finnish OA cases and families K/L score 2–3 K/L ≥ 3 for index cases and K/L ≥2 for their siblings (DIP
bilateral)
Framingham Osteoarthritis Study K/L score 2 K/L ≥ 2 (one definite osteophyte): joint specific definitions (i.e.,
DIP OA, PIP OA etcetera)
GARP K/L score 2 ≥3 joints (DIP/PIP/CMC1) affectedc
HCS - - Presence of Heberden's or Bouchard's nodes
LUMEN - - Presence of OA (JSN grade ≥2 or osteophyte grade ≥2 or JSN
grade 1 plus osteophyte grade 1) in at least 1 DIP or PIP joint in
each hand symmetrically or at least 2 DIP/PIP joints in the same
hand in a pattern consistent with primary OA (in the same row or
ray) or the CMC1 joint bilaterally.
RSI K/L score 2 2 out of 3 hand joint groups (DIP/PIP/CMC1 or TS) affecteda
TwinsUK K/L score 2 ≥3 joints (DIP/PIP/CMC1) affecteda
OA = osteoarthritis; K/L = Kellgren and Lawrence; - no standard classification system is used to define OA; DIP = distal interphalangeal joint; PIP
= proximal interphalangeal joint; CMC1 = first carpometacarpal joint; TS = trapezioscaphoid joint; MCP = metacarpophalangeal joint; D&T =
Dentists and Teachers Study; GARP = Genetics osteoARthritis and Progression; HCS = Hertfordshire Cohort Study; RSI = Rotterdam Study-I
a
affected means K/L ≥ 2 (=definite osteophyte) in each or both hands
b
affected means modified K/L ≥ 2 (=a single radiographic sign indicative of OA, slight to moderate lowering of the joint space, sometimes
subluxation, minimal osteophytes, degeneration cysts or slight marginal sclerosis, each of the latter signs without a clear narrowing of joint space
but little if any additional pathology) irrespective of right or left hand
c
affected means K/L ≥ 2 (=definite osteophyte) irrespective of left or right hand.
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Table 2c
Description of the radiographic hip OA definition according to 7 studies of the TREAT-OA consortium
Study Classification System Cut-off valuefor OA Exact OA definition
Chingford Study K/L score 2 Definite osteophyte
GARP Study K/L score 2 Definite JSN + definite osteophyte
MrOS Modified Croft grade 2 Presence of either definite JSN or definite osteophytes plus at least 1 of 5other features: osteophytes, JSN, sclerosis, cysts or femoral head deformity
RSI K/L score 2 Definite JSN + definite osteophyte
RSII K/L score 2 Definite JSN + definite osteophyte
SOF Modified Croft grade 2 Presence of either definite JSN or definite osteophytes plus at least 1 of 5other features: osteophytes, JSN, sclerosis, cysts or femoral head deformity
TwinsUK Croft grade 1 Definite osteophytes
OA = osteoarthritis; K/L = Kellgren and Lawrence; JSN = joint space narrowing; GARP = Genetics osteoARthritis and Progression; MrOS =
Osteoporotic Fractures in Men Study; RSI = Rotterdam Study-I; RSII = Rotterdam study-II; RSIII = Rotterdam Study-III; SOF = Study of
Osteoporotic Fractures
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Table 3a
Description of the symptomatic knee OA definitions according to 10 studies of the TREAT-OA consortium
Study OA definition based on: Exact OA definition
Chinese Case-Control Study K/L grade + symptoms
K/L ≥ 2 (=one definite osteophyte) + pain with rest and/or night pain of over
5-month duration. Exclusion of inflammatory, posttraumatic, post septic
arthritis, dysplasias
deCODE Hospital records of TJR TKR. A clinician reviewed the patients records to verify the diagnosis
Greek clinical cases TJR due to OA reported byspecialist TKR + K/L ≥ 2 (=definite osteophytes + possible JSN)
Health 2000 Clinical records of OA orTKR
History, records and a standardized clinical diagnosis of previously diagnosed
knee OA or knee arthroplasty due to OA based on convincing findings OR at
least moderately restricted mobility OR slightly restricted mobility and either
of the following: documented history of previously diagnosed knee OA but not
convincingly presented grounds for the diagnosis or typical symptoms of knee
OA






First knee arthroplasty or high tibial osteotomy + diagnosis of OA according to
the International Classification of Disease (ICD) 9 and 10
Nottingham Case-Control
Clinically severe knee OA
based on hospital
orthopaedic surgery lists
Referred to the hospital with symptomatic, clinically severe knee OA and the
majority had undergone unilateral or bilateral TKR within the previous 5
years. Pre-operative knee radiographs were examined to confirm the diagnosis.
Exclusion based on another major arthropathy, Paget's disease
Oxford Study Severe symptomatic kneeOA + K/L grade
Signs and symptoms of OA sufficiently severe to require TKR + K/L ≥ 2
(exact definition unknown). Exclusion based on dysplasia
Spanish clinical cases TJR
TKR, a rheumatologists considered patients to suffer from severe primary OA.
Exclusion based on inflammatory, infectious, traumatic or congenital joint
pathology and lesions due to crystal deposition or osteonecrosis
VIDEO K/L grade + pain K/L ≥ 2 (=one definite osteophyte) + medial joint space width > 1mm + kneepain
OA = osteoarthritis; TJR = total joint replacement; TKR = total knee replacement; JSN = joint space narrowing; MDC = Malmö Diet and Cancer
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Table 3b
Description of the symptomatic hand OA definitions according to 2 studies of the TREAT-OA consortium
Study OA definition based on: Exact OA definition
deCODE Patients records at hospitalsand health centres
Included on the basis of clinical examination by an experienced examiner,
supported by a radiograph for >60% of the cases
Spanish clinical cases ACR criteria Patients were complaining of hand OA and followed in the Rheumatology Unit.The ACR criteria were used for inclusion in the study
OA = osteoarthritis; ACR = American College of Rheumatology
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Table 3c
Description of the symptomatic hip OA definitions according to 8 studies of the TREAT-OA consortium
Study OA definition based on: Exact OA definition
deCODE Hospital records of TJR THR. A clinician reviewed the patients records to verify the diagnosis
Health 2000 Clinical records of OA or THR
History, records and a standardized clinical diagnosis of previously
diagnosed hip OA or hip arthroplasty due to OA based on convincing
findings OR at least moderate restrictions in extension or in inner
rotation or in outer rotation OR slight restrictions in extension, inner
rotation, outer rotation or at least moderately restricted abduction-
adduction and either of the following: documented history of previously
diagnosed hip OA but no grounds for the diagnosis is given or typical
symptoms of hip OA
Japanese Case-Control Study Symptoms + radiographs
Subjects are symptomatic and were treated in participating institutions
on a regular basis + radiographic signs of hip OA (exact definition
unknown)
MDC Study
Incident hip arthroplasty from
national Swedish hospital
discharge register
First hip arthroplasty in combination with a contemporaneous diagnosis
of hip osteoarthritis according to the International Classification of
Disease (ICD) 9 and 10
Nottingham Case-Control
Clinically severe hip OA based
on hospital orthopaedic surgery
lists
Referred to the hospital with symptomatic, clinically severe hip OA and
the majority had undergone unilateral or bilateral THR within the
previous 5 years. Pre-operative hip radiographs were examined to
confirm the diagnosis. Exclusion based on another major arthropathy,
Paget's disease, overt child hip disease, THR due to trauma or terminal
illness
Oxford Study Severe symptomatic hip OA + K/L grade
Signs and symptoms of OA sufficiently severe to require THR + K/L ≥
2 (exact definition unknown). Exclusion based on dysplasia
Sheffield Study THR
Subjects had undergone THR for clinical, idiopathic OA that was
confirmed radiographically prior to joint replacement (exact
radiographic definition uknown)
Spanish clinical cases TJR
THR, a rheumatologists considered patients to suffer from severe
primary OA. Exclusion based on inflammatory, infectious, traumatic or
congenital joint pathology and lesions due to crystal deposition or
osteonecrosis
OA = osteoarthritis; TJR = total joint replacement; THR = total hip replacement; MDC = Malmö Diet and Cancer
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Table 6
Baseline characteristics of 6 cohort studies with ROA phenotypes involved in the standardization process
Study Mean age (range) Mean body mass index (range)
Chingford Study 54 (44–67) 26 (17–47)
Framingham Osteoarthritis Study 64 (29–93) 26 (14–54)
Hertfordshire Cohort Study 65 (59–71) 27 (17–48)
Osteoporotic Fracture in Men Study 77 (69–97) 27 (18–50)
ROAD Study 70 (23–94) 23 (13–37)
Rotterdam Study I 68 (55–94) 26 (15–59)
Rotterdam Study III 57 (45–89) 28 (14–57)
Study of Osteoporotic Fractures 71 (65–91) 27 (16–59)
TwinsUK 54 (37–76) 25 (15–51)
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